Friday, September 28

7:30 am

Registration Desk Opens & Continental Breakfast
(Lobby, Eric P. Newman Education Center)


Welcome & Opening Remarks: Setting the Stage for Secondary Prevention Trials in Alzheimer's Disease 

John C. Morris, MD, Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology, Professor of Pathology and Immunology, Professor of Physical Therapy, and Professor of Occupational Therapy at Washington University School of Medicine, Director, Knight Alzheimer's Disease Research Center, Washington University School of Medicine


Mechanisms and Models of Cerebral Amyloidosis

Mathias Jucker, PhD, Hertie-Institute for Clinical Brain Research, University of Tübingen and German Center for Neurodegenerative Diseases (DZNE), Tübingen


Trans-synaptic Propagation of Tauopathy - Anatomic Considerations, Mechanistic Insight and Therapeutic Possibilities

Karen Duff, PhD, Professor, Department of Pathology and Cell Biology Columbia University Medical Center, and Department of  Integrative Neuroscience, New York State Psychiatric Institute




Adapting Proteostasis to Ameliorate Aggregation-Associated Degenerative Diseases

Jeffery W. Kelly, PhD, Lita Annenberg Hazen Professor of Chemistry, Chairman, Department of Molecular and Experimental Medicine, The Scripps Research Institute


Development of Statins for Treatment of Hypercholesterolemia

Scott Grundy, MD, PhD, Professor, Distinguished Chair in Human Nutrition, UT Southwestern Medical Center



Moderator:  David Holtzman, MD, Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology, Professor of Developmental Biology, Associate Director of the Alzheimer's Disease Research Center, Washington University School of Medicine     


Lunch/Poster Session – Eric P. Newman Center Lobby


The ‘A4’ Trial: Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease

Reisa A. Sperling, MD, Director, Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital, Harvard Aging Brain Study, Massachusetts General Hospital, Associate Professor of Neurology, Harvard Medical School


Alzheimer’s Prevention Initiative

Eric M Reiman, MD, Executive Director, Banner Alzheimer’s Institute


Dominantly Inherited Alzheimer Network Trials:  An Opportunity to Prevent Dementia

Randall J. Bateman, MD, Charles F. and Joanne Knight Distinguished Professor of Neurology, Washington University in St. Louis 




Clinical Trial Design for Disease-Modifying Treatments for Alzheimer’s Disease:  Challenges and Opportunities

Steven M. Paul, MD, Director, Helen and Robert Appel Alzheimer’s Disease Research Institute, Professor of Neuroscience, Psychiatry and Pharmacology,
Weill Cornell Medical College


Effect of FAD Mutations on the Enzymatic Activity of Gamma-Secretase

Bart De Strooper, MD, PhD, VIB Center for the Biology of Disease, VIB Center for Human Genetics, KU Leuven


Challenges in Selecting Biomarker Outcomes in AD Clinical Trials

Stephen Salloway, MD, MS, Professor of Neurology and Psychiatry, The Warren Alpert Medical School, Brown University, Director of Neurology and the Memory and Aging Program, Butler Hospital


Trial Design: Cognitive Outcomes

Laurie Ryan, PhD, Program Director, Alzheimer's Disease Clinical Trials, Division of Neuroscience, National Institute on Aging


Four Generations of Early Onset Alzheimer’s Disease

Rachel C. Huber and Joe Heinrichs, DIAN Participants



Moderator:  Alison Goate, DPhil, Professor of Genetics, Department of Psychiatry, Professor of Genetics, Department of Neurology, Neurology, Director, Hope Center for Neurological Disorders, Washington University School of Medicine


Symposium Closing Reception and Poster Session – Eric P. Newman Center Lobby